Genentech's Immuno-Oncology Agent Promising in Advanced Breast Cancer

The monoclonal antibody MPDL3280A, a PD-L1 inhibitor being developed by Genentech, generated pharmacodynamic responses as measured by circulating biomarkers in phase 1a studies in patients with triple negative breast cancer.

In patients with metastatic triple-negative breast cancer, immunotherapy with the monoclonal antibody MPDL3280A appeared to be safe, tolerable, and capable of durable clinical activity, according to results from an ongoing multicenter phase Ia study. "The latest analysis of our data revealed a 24-week progression-free survival rate of 27% with an objective response rate of 19%, and 3 of 4 responses are ongoing," reported Leisha A. Emens, MD, PhD, of Johns Hopkins University, and colleagues in a press release at the American Association for Cancer Research annual meeting.

"MPDL3280A was generally well tolerated and demonstrated promising efficacy in pretreated metastatic PD-L1 IHC 2 or 3 TNBC patients," she added. "Furthermore, circulating biomarker analyses revealed pharmacodynamic responses to MPDL3280A."

Link to the complete article on Medpage: